At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 207 enrolled
Drug / intervention
Nemonoxacin 500 mg +2 moredrug
Likely dose
Nemonoxacin 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Randomized, Double-Blind, Parallel Comparative, Phase II Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Versus Moxifloxacin in Treating Adult Patients With Community-Acquired Pneumonia
In Brief
A Phase 2 clinical trial evaluating Nemonoxacin 500 mg, Nemonoxacin 650 mg, and 1 other intervention for Pneumonia. Completed, enrolled 207 participants across 2 sites in 2 countries.
Detailed Summary
The purpose of this study is to Evaluate the Efficacy, safety and pharmacokinetics of Intravenous Nemonoxacin Compared with Intravenous Moxifloxacin in Adult Patients with community-acquired pneumonia (CAP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumonia
CountriesChina, Taiwan
CollaboratorsQPS-Qualitix, R&G Pharma Studies Co.,Ltd.
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2013
First PostedSep 2013
Primary CompletionDec 2013
TodayJul 2026
First PostedSep 18, 2013
Enrollment StartMar 1, 2013
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 12.8 years ago
Interventions
Nemonoxacin 500 mgdrug
IV Infusion, once daily for 7\~14 days
Nemonoxacin 650 mgdrug
IV Infusion, once daily for 7\~14 days
Moxifloxacin 400 mgdrug
IV Infusion, once daily for 7\~14 days